Literature DB >> 24419055

Role of oxidative stress and selenium in Graves' hyperthyroidism and orbitopathy.

C Marcocci1, L Bartalena.   

Abstract

Graves' hyperthyroidism and its main extrathyroidal manifestation, Graves' orbitopathy (GO) are characterized by an increased oxidative stress. Treatment of hyperthyroidism with antithyroid drugs is usually associated with an amelioration of biochemical parameters associated with oxidative stress. Association of antithyroid drugs with antioxidants may favor a prompter control of thyroid hyperfunction. Reactive oxygen species may contribute to the pathogenesis of GO. A recent, large, multicenter, randomized, placebo-controlled clinical trial in patients with mild GO clearly demonstrated that selenium supplementation has beneficial effects on the quality of life and the overall ophthalmic involvement of these patients, while reducing the risk of progression to more severe forms of GO.

Entities:  

Year:  2013        PMID: 24419055

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  8 in total

1.  Assesment of oxidative status and its association with thyroid autoantibodies in patients with euthyroid autoimmune thyroiditis.

Authors:  Husniye Baser; Ummugulsum Can; Salih Baser; Fatma Humeyra Yerlikaya; Uysaler Aslan; Bahauddin Taha Hidayetoglu
Journal:  Endocrine       Date:  2014-08-23       Impact factor: 3.633

2.  Serum prolidase levels in Graves' disease without ophthalmopathy and its association with oxidative status.

Authors:  H Korkmaz; S Tabur; M Ozkaya; E Oguz; N Aksoy; E Akarsu
Journal:  J Endocrinol Invest       Date:  2015-04-22       Impact factor: 4.256

3.  Stimulatory TSH-Receptor Antibodies and Oxidative Stress in Graves Disease.

Authors:  Tanja Diana; Andreas Daiber; Matthias Oelze; Susanne Neumann; Paul D Olivo; Michael Kanitz; Paul Stamm; George J Kahaly
Journal:  J Clin Endocrinol Metab       Date:  2018-10-01       Impact factor: 5.958

4.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

Review 5.  Extrathyroidal manifestations of Graves' disease: a 2014 update.

Authors:  Luigi Bartalena; Vahab Fatourechi
Journal:  J Endocrinol Invest       Date:  2014-06-10       Impact factor: 4.256

6.  Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves' Disease Hyperthyroidism During Methimazole Treatment.

Authors:  Daniela Gallo; Lorenzo Mortara; Giovanni Veronesi; Simona Am Cattaneo; Angelo Genoni; Matteo Gallazzi; Carlo Peruzzo; Paolo Lasalvia; Paola Moretto; Antonino Bruno; Alberto Passi; Andrea Pini; Andrea Nauti; Maria Antonietta Lavizzari; Michele Marinò; Giulia Lanzolla; Maria Laura Tanda; Luigi Bartalena; Eliana Piantanida
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-15       Impact factor: 6.055

7.  Cigarette Smoke Extract-Induced Oxidative Stress and Fibrosis-Related Genes Expression in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.

Authors:  Hui-Chuan Kau; Shi-Bei Wu; Chieh-Chih Tsai; Catherine Jui-Ling Liu; Yau-Huei Wei
Journal:  Oxid Med Cell Longev       Date:  2016-06-02       Impact factor: 6.543

8.  Alteration in Prooxidant-antioxidant Balance Associated with Selenium Concentration in Patients with Congenital Hypothyroidism.

Authors:  Shilan Rostami; Asadollah Fathollahpour; Mohammad Abdi; Kejal Naderi
Journal:  J Med Biochem       Date:  2018-07-01       Impact factor: 3.402

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.